Navigation Links
Study challenges baby formula claim
Date:7/14/2011

Despite the formula being recommended in public health guidelines set out by the Australasian Society of Clinical Immunology and Allergy, the new study, published online in the Journal of Allergy and Clinical Immunology, found there was no benefit in using hypoallergenic (partially hydrolysed whey) formula to prevent allergies in high-risk infants up to seven years of age, compared to a conventional cow's milk based formula.

The trial, which is one the largest to test the effect of hypoallergenic baby formula, involved 620 infants and assessed whether using the formula decreased the risk of allergy in later life.

Infants in the study were given either hypoallergenic, cow's milk or soy formula after the cessation of breastfeeding. Allergy testing was undertaken at six, 12 and 24 months and children were followed up again at six or seven years of age.

Lead authors David Hill, a Senior Consultant Allergist at the Murdoch Childrens Research Institute and Adrian Lowe, a research fellow at the Murdoch Childrens Research Institute and the Centre for MEGA Epidemiology, the University of Melbourne said their findings did not support the recommendations that hypoallergenic formula should be used after breast feeding as a preventive strategy for infants at high risk of allergenic disease.

"In our study of high risk children, this 'hypoallergenic' formula did not show any beneficial effect, when compared with a normal cows' milk based formula, for the prevention childhood eczema, asthma or hay fever up to seven years of age," Dr Lowe said.

Dr Hill said: "Our findings do not support the role of hypoallergenic formula for the prevention of allergic disease. Families at high risk of allergy should continue to be encouraged to breast feed for the many known benefits associated with breastfeeding."


'/>"/>

Contact: Charlotte Crawford
charlotte.crawford@unimelb.edu.au
University of Melbourne
Source:Eurekalert

Page: 1

Related biology news :

1. Study explains why men are at higher risk for stomach cancer
2. First study into GM Atlantic salmon mating reveals danger of escape to wild gene pool
3. Your mother was right: Study shows good posture makes you tougher
4. Researchers study pesticide pathways into the atmosphere
5. Scleroderma study identifies roadblocks to employment
6. Study: People at risk for panic buffered from stressor by high levels of physical activity
7. UCI study points to new means of overcoming antiviral resistance in influenza
8. Owl study expands understanding of human stereovision
9. Virginia Tech Coal and Energy Center selected for study of CO2 injection into storage reservoirs
10. Large human study links phthalates, BPA and thyroid hormone levels
11. University of Houston researcher an author of multi-institutional genetic study of ovarian cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2016)... , Dec 16, 2016 Research and Markets ... Market - Global Forecast to 2021" report to their offering. ... The biometric ... grow at a CAGR of 14.06% from 2016 to 2021. The ... is projected to reach 854.8 Million by 2021. The growth of ...
(Date:12/15/2016)... ... announced the addition of the "Global Military Biometrics Market 2016-2020" ... military biometrics market to grow at a CAGR of 7.5% during the ... an in-depth market analysis with inputs from industry experts. The report covers ... report also includes a discussion of the key vendors operating in this ...
(Date:12/12/2016)... , Dec. 12, 2016  Researchers at Trinity ... for graphene by combining the material with Silly ... sensitive pressure detector able to sense pulse, blood ... small spider.  The research team,s ... be read here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... ... 17, 2017 , ... Pono Ola , a mind-body wellness firm on ... the official launch of its much-anticipated Pono Board: a re-invented fitness and anti-fatigue balance ... for over a year, the patented Pono Board is the world’s only exercise balance ...
(Date:1/17/2017)...  Protagonist Therapeutics, Inc. (NASDAQ: PTGX ... global Phase 2b induction study in ulcerative colitis ... integrin. The aim of this randomized, double-blind, placebo-controlled, ... and efficacy of PTG-100 in approximately 240 adult ... disease. "We are very pleased ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... Tibbetts Award from the U.S. Small Business Administration. The Tibbetts Award ... economic or social impact […] and are considered the best of the best ...
(Date:1/13/2017)... Research and Markets has announced the addition ... Forecast to 2021" report to their offering. ... The biosimilars market is expected ... in 2016, at a CAGR of 26.3%. The ... type, and application. Factors such as rising incidence of various diseases, ...
Breaking Biology Technology: